Hologic, Inc. (NASDAQ:HOLX) Stock Position Lowered by Bridgewater Associates LP

Bridgewater Associates LP trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 48.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 164,827 shares of the medical equipment provider’s stock after selling 152,507 shares during the period. Bridgewater Associates LP owned 0.07% of Hologic worth $13,427,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in HOLX. Prentiss Smith & Co. Inc. grew its holdings in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after buying an additional 130 shares in the last quarter. Covestor Ltd grew its stake in Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the period. Massmutual Trust Co. FSB ADV lifted its position in shares of Hologic by 20.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock worth $62,000 after purchasing an additional 140 shares in the last quarter. Finally, Empirical Finance LLC boosted its holdings in shares of Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

NASDAQ:HOLX opened at $79.44 on Friday. The firm has a market capitalization of $18.45 billion, a PE ratio of 23.86, a PEG ratio of 2.51 and a beta of 0.98. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm’s fifty day simple moving average is $80.28 and its 200 day simple moving average is $78.42.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the company posted $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Analyst Ratings Changes

HOLX has been the subject of a number of research analyst reports. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and cut their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Leerink Partners cut their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada increased their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.